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PET/MRIPreclinical and clinical studies have demonstrated the signiﬁcance of inﬂammation and autoantibodies in epilepsy,
and the use of immunotherapies in certain situations has become an established practice. Temporal lobe epilepsy
can follow paraneoplastic or nonparaneoplastic limbic encephalitis associated with antibodies directed against
brain antigens. Here, we focus on a patient with worsening confusion and temporal lobe seizures despite
treatment with antiepileptic medications. Serial brain MRIs did not conclusively reveal structural abnormalities,
so the patient underwent brain PET/MRI to simultaneously evaluate brain structure and function, revealing
bitemporal abnormalities. The patient was diagnosed with voltage-gated potassium channel antibody-related
limbic encephalitis based on clinical presentation, imaging ﬁndings, and antibody testing. Treatment included
the addition of a second antiepileptic agent and oral steroids. His seizures and cognitive deﬁcits improved and
stabilized.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The detection of novel autoantibodies has provided etiological
insight into epileptic disorders of previously unknown causes. Forerun-
ners in this area of investigation include voltage-gatedpotassiumchannel
(VGKC) antibodies, antibodies against the N-methyl-D-aspartate receptor
(NMDAR), and antibodies against glutamic acid decarboxylase (GAD).
Other noteworthy antibodies include those against AMPA receptors and
the GABAB receptor as well as against onconeural antigens [1,2]. Often,
the diagnosis of an autoantibody-related epileptic disorder is made
during the evaluation of an acute limbic encephalitis (LE), at timeswithin
the setting of drug-resistant status epilepticus. However, autoantibody
testing has also returned positive results during the recovery phase of
an apparent monophasic illness with acute seizures or in patients with
less severe chronic epilepsy [3]. At times, the positive antibodies are not
clearly directly causative for seizures but may be nonspeciﬁcally raised
and serve as immune markers, implicating that there is a signiﬁcant
inﬂammatory component. The discovery of autoantibodies typically trig-
gers a neoplastic evaluation. For example, a signiﬁcant subset of patients
diagnosed with anti-NMDAR encephalitis is found to have ovarian1 314 362 0296.
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. This is an open access article underteratomas, which are therapeutically removed [3]. But in many cases,
these antibodies are nonparaneoplastic, and immunotherapy may be
the only major intervention along with antiepileptic medications.
We describe a clinical case in which the use of antibody testing and
PET/MRI imaging aided in the identiﬁcation of voltage-gated potassium
channel antibody-related limbic encephalitis (VGKC-LE). Magnetic reso-
nance imaging ﬁndings alone did not deﬁnitively demonstrate structural
abnormalities, even when repeated over time, despite clinical observa-
tions that his memory and cognition were progressively worsening. In
addition to antibody testing, brain PET was obtained to evaluate for
regions of hypometabolic abnormalities that might support our clinical
suspicions of a limbic encephalitis. We were fortunate to have access to
PET/MRI technology at our institution, which was used in this case.
In vivo-dedicated brain PET/MRI is a novel multimodal technology
that allows for the noninvasive simultaneous acquisition of high-
resolution structural data and functional imaging within the same
scanning period [4,5]. Conceptually similar to standard PET/CT,
PET/MRI offers better structural imaging of most body tissues than
PET/CT, especially soft tissue, and uses a much lower dose of radiation
[6]. The synergistic potential of PET/MRI is its greatest strength. The
ability to immediately analyze superimposed, coregistered images
makes it possible to detect anatomical features and pathology that
might have gone underappreciated with separately acquired single
modality tests. Areas of differential metabolism or ligand speciﬁcity on
PET can be examined more carefully for structural identiﬁcation
and analysis using MRI, and the limitations that currently exist for thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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resolution afforded by immediate, precise coregistration of the MRI
[5]. We present the PET/MRI images to showcase this novel technology
and to present ﬁndings in a patient suffering from VGKC-LE.
2. Materials and methods
A single patient underwent an inpatient evaluationwhich included a
comprehensive paraneoplastic panel and brain PET/MRI imaging using
a Siemens Biograph mMR system. Visual analysis of the imaging was
performed by neuroradiologists.
3. Case report
A 64-year-old, right-handed man presented in referral for an
11-month history of seizures. Witnessed episodes during wakeful-
ness included behavioral arrest, staring, and confusion lasting
minutes, which had progressively increased in frequency to multiple
per day. He also had nocturnal episodes of arousal, moaning, repeti-
tive hand movements, and confusion lasting seconds. The patient
had no memory of these events. Despite initial treatment with leve-
tiracetam, titrated to 2000 mg twice daily, he continued to haveFig. 1. Axial T2/FLAIR images obtained four months apart at the level of the temporal lobes (A
bilaterally in the mesial temporal structures and insula was present, but not deﬁnitively abnorworsening memory, behavioral changes, difﬁculty paying bills, and
trouble navigating his own home. His personality changed from
reserved to outgoing.
Extensive evaluation 6 months from onset, including head CT, CBC,
CMP, UA, vitamin B12 testing, thyroid testing, coagulation proﬁle,
creatine kinase, and CSF HSV-1 PCR, was unremarkable. A lumbar punc-
ture showed elevated protein at 72 mg/dL, and EEG revealed left
frontotemporal epileptiform abnormalities. An initial brain MRI with
contrast and another repeated four months later showed possibly
increased T2-weighted signal in the bilateral medial temporal lobes
and insular cortex. However, the appearance of these areas did not
signiﬁcantly change over time despite his progressively worsening
symptoms (Fig. 1).
During reevaluation on presentation to our institution, a repeat
lumbar puncture again showed elevated protein at 72 mg/dL without
other abnormalities. Video-EEG captured bitemporal seizures and
epileptiformdischarges. Brain PET/MRI revealed bitemporal and bilateral
insular hypometabolism (Fig. 2). Voltage-gated potassium channel anti-
bodies were present. Otherwise, extensive infectious, autoimmune,
neoplastic, paraneoplastic, prion disease workup, CT of the chest, abdo-
men, and pelvis, and body MRI were unrevealing. Treatment included
the addition of lamotrigine as a second antiepileptic agent and oral. initial, B. follow-up) and insula (C. initial, D. follow-up). The somewhat increased signal
mal, and did not signiﬁcantly change over time.
Fig. 2.A. andD. Axial T2/FLAIRMRI at the level of the temporal lobes and insula, respectively, with possiblemesial temporal and insular hyperintensities; C. and F. FDG-PET images at these
levels showing bitemporal and bilateral insular hypometabolism; B. and E. CoregisteredMRI and PET at these levels, showing where the areas of hypometabolism align with the detailed
neuroanatomy.
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other weekend for 8 doses). His seizures and cognitive deﬁcits improved
and stabilized.
4. Discussion
This patient presented with a clinical picture of medically refractory
temporal lobe epilepsy complicated by memory and cognitive
problems. The majority of testing was unrevealing, and even brain
MRI repeated over time did not show any deﬁnitive structural abnor-
malities to support an active region-speciﬁc pathological process. As
the patient's behavior and thinking progressively worsened, the possi-
bility of an ongoing limbic encephalitis was evaluated by comprehen-
sive paraneoplastic antibody panel and advanced brain imaging. Brain
PET/MRI technology, available at our institution, afforded us the oppor-
tunity to repeat the brain MRI once more while also simultaneouslyassessing for functional abnormalities using PET. The PET/MRI ﬁndings
proved to be key supportive evidence of bilateral temporal and insular
abnormalities where serial MRI had fallen short. Although bilateral
hypometabolism in these regions is not speciﬁc for limbic encephalitis
and could be seen in patientswith other forms of temporal lobe epilepsy,
the PET/MRI results were concordant with the clinical suspicion. These
results along with positive VGKC antibodies clariﬁed the diagnosis and
improved conﬁdence in moving forward with both additional antiepi-
leptic treatment and immunotherapy, which ultimately kept the patient
seizure-free and signiﬁcantly improved his cognition.
Voltage-gated potassium channel antibody-related limbic encepha-
litis typically includes encephalopathy, seizures, and mesial temporal
lobe structural abnormalities [7–10]. Classically, regional abnormalities
in the mesial temporal lobes in VGKC-LE are not seen in other VGKC
antibody-related neurological disorders, namely Morvan's or Isaac's
syndromes [11]. Imaging abnormalities typical of VGKC-LE have also
26 B.K. Day et al. / Epilepsy & Behavior Case Reports 4 (2015) 23–26been reported in patients manifesting personality changes andmemory
deﬁcits without evidence of seizures [12,13]. Furthermore, patients
with VGKC-LE have been reported to have a normal brain MRI but
bitemporal hypometabolism on brain PET [14], similar to ﬁndings in
our patient.
This is the ﬁrst study reporting PET/MRI ﬁndings in VGKC-LE.
However, correlations of PET and MRI in VGKC-LE have previously
been described. In seven patients with subacute limbic encephalitis,
one with VGKC antibodies, the authors reported that the neuroimaging
ﬁndings of PET and MRI did not overlap in half the patients but, when
combined, revealed temporal pathology in all of them [15]. One patient
with VGKC-LE had serial brain MRI and PET studies for two years,
revealing a successive switch in prominence from right to left mesial
temporal lobe changes. Of special relevance to the case presented, the
PET ﬁndings were prominent earlier than the MRI ﬁndings during the
development of left mesial temporal pathology, despite over a year of
seizures prior to that time [16].
5. Conclusions
In this case report, the use of brain PET/MRI and antibody testing aided
in the diagnosis of VGKC-LE. Antibody testing should be considered in
cases of acute epilepsies of unknown cause, especially if they are drug-
resistant or severely debilitating. Brain PET and MRI are complementary
technologies for assessing regional abnormalities, and brain PET may
reveal focal ﬁndings in patients with VGKC-LE missed by brain MRI
alone. Simultaneous brain PET/MRI multimodal technology has synergis-
tic potential for identifying focal abnormalities that separately-acquired
single modality testing might miss.
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